Ori Biotech’s Chief Digital Officer Kevin Gordon discusses the key pain points that are preventing patients from accessing this new generation of curative therapies.
Kai Lipinski, PhD, chief scientific officer of Vibalogics, a Recipharm company, focuses on oncolytic viruses (OVs); explaining how early-stage drug developers can overcome the challenges in scaling up and commercialising their products.
Dr. Nandu Deorkar, senior vice president, research & development at Avantor, addresses the manufacturing challenges that remain when developing cell and gene therapies at scale.
Nick Porter, World Courier, and Chris Williams, Alloga Europe, discuss the heightened demand for cold chain and cryogenic storage to support advanced therapy medicinal products (ATMPs) and the solutions needed to safeguard the supply chain.
Kerstin Pohl, sr. global manager, Gene Therapies, at SCIEX, and Thomas Kofoed, co-founder of Alphalyse, discussed the harmful effects of HCPs and strategies to mitigate them.
Laura A. Kerepesi, PhD, associate director – Preclinical Manufacturing, Andelyn Biosciences shares insight on the key learnings from 2022 within the C> sector, as well as upcoming 2023 trends around gene therapy.
Experts from Watson-Marlow Fluid Technology Solutions and National Institute for Bioprocessing Research and Training (NIBRT) discuss the advantages of single-use technologies in CGT manufacturing platforms.
BioIVT’s Trevor Smith, MS, MBA, product manager, immune cells, describes necessary considerations when preparing to manufacture a cell or gene therapy, from starting materials to safety endpoints.
Allison Hoffman, global product manager, Cell Therapy Technologies, Terumo BCT, discusses how automation is leading the way to optimising autologous manufacturing in the C> sector.
EPM chats with Pratima Cherukuri, chief scientific officer, Genezen, who shares the considerations in the development and manufacture of lentiviral vectors, and highlights some of the challenges organisations may face along the way.
Natasha Rivas, vice president of quality and regulatory, and Jose Cruz, director of vector manufacturing at Genezen, explore the difficulties in ensuring cGMP compliance is achieved throughout viral vector production.
Polling conducted across six European countries, with over 6,000 respondents, finds high levels of excitement for gene therapy and medical innovation, particularly for the treatment of rare diseases.
